These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 20513319)

  • 1. Predictors of initiating rapid-acting insulin analog using vial/syringe, prefilled pen, and reusable pen devices in patients with type 2 diabetes.
    Lee LJ; Anderson J; Foster SA; Corrigan SM; Smith DM; Curkendall S
    J Diabetes Sci Technol; 2010 May; 4(3):547-57. PubMed ID: 20513319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adherence to premixed insulin in a prefilled pen compared with a vial/syringe in people with diabetes in Singapore.
    Cheen HH; Lim SH; Huang MC; Bee YM; Wee HL
    Clin Ther; 2014 Jul; 36(7):1043-53. PubMed ID: 24913030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus.
    Korytkowski M; Bell D; Jacobsen C; Suwannasari R;
    Clin Ther; 2003 Nov; 25(11):2836-48. PubMed ID: 14693308
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of utilization, cost, adherence, and hypoglycemia in patients with type 2 diabetes initiating rapid-acting insulin analog with prefilled pen versus vial/syringe.
    Lee LJ; Li Q; Reynolds MW; Pawaskar MD; Corrigan SM
    J Med Econ; 2011; 14(1):75-86. PubMed ID: 21231863
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health care costs and medication adherence associated with initiation of insulin pen therapy in medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
    Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
    Clin Ther; 2007; 29 Spec No():1294-305. PubMed ID: 18046929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical impact of initiating insulin glargine therapy with disposable pen versus vial in patients with type 2 diabetes mellitus in a managed care setting.
    Davis SN; Wei W; Garg S
    Endocr Pract; 2011; 17(6):845-52. PubMed ID: 21550952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health care costs and medication adherence associated with initiation of insulin pen therapy in Medicaid-enrolled patients with type 2 diabetes: a retrospective database analysis.
    Pawaskar MD; Camacho FT; Anderson RT; Cobden D; Joshi AV; Balkrishnan R
    Clin Ther; 2007 Jun; 29(6 Pt 1):1294-305. PubMed ID: 18036391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of insulin delivery pen devices.
    Kroon L
    J Am Pharm Assoc (2003); 2009; 49(5):e118-31. PubMed ID: 19692314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of insulin pen devices.
    McCoy EK; Wright BM
    Postgrad Med; 2010 May; 122(3):81-8. PubMed ID: 20463417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing patient preferences and healthcare provider recommendations with the pen versus vial-and-syringe insulin delivery in patients with type 2 diabetes.
    Ahmann A; Szeinbach SL; Gill J; Traylor L; Garg SK
    Diabetes Technol Ther; 2014 Feb; 16(2):76-83. PubMed ID: 24266497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Humalog(®) KwikPen™: an insulin-injecting pen designed for ease of use.
    Schwartz SL; Ignaut DA; Bodie JN
    Expert Rev Med Devices; 2010 Nov; 7(6):735-43. PubMed ID: 21050084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics Relating to Adherence and Persistence to Basal Insulin Regimens Among Elderly Insulin-Naïve Patients with Type 2 Diabetes: Pre-Filled Pens versus Vials/Syringes.
    Slabaugh SL; Bouchard JR; Li Y; Baltz JC; Meah YA; Moretz DC
    Adv Ther; 2015 Dec; 32(12):1206-21. PubMed ID: 26563324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-world rates, predictors, and associated costs of hypoglycemia among patients with type 2 diabetes mellitus treated with insulin glargine: results of a pooled analysis of six retrospective observational studies.
    Xie L; Wei W; Pan C; Baser O
    J Med Econ; 2013 Sep; 16(9):1137-45. PubMed ID: 23859434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis.
    Xie L; Zhou S; Pinsky BW; Buysman EK; Baser O
    Diabetes Technol Ther; 2014 Sep; 16(9):567-75. PubMed ID: 24735083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative device assessments: Humalog KwikPen compared with vial and syringe and FlexPen.
    Ignaut DA; Schwartz SL; Sarwat S; Murphy HL
    Diabetes Educ; 2009; 35(5):789-98. PubMed ID: 19783767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does pen help? A real-world outcomes study of switching from vial to disposable pen among insulin glargine-treated patients with type 2 diabetes mellitus.
    Xie L; Zhou S; Wei W; Gill J; Pan C; Baser O
    Diabetes Technol Ther; 2013 Mar; 15(3):230-6. PubMed ID: 23336845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prefilled pen versus prefilled syringe: a pilot study evaluating two different methods of methotrexate subcutaneous injection in patients with JIA.
    Roszkiewicz J; Swacha Z; Smolewska E
    Pediatr Rheumatol Online J; 2020 Aug; 18(1):64. PubMed ID: 32787934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trend analyses of insulin delivery systems in the United States.
    Lee LJ; Li Q; Reynolds MW; Engelman W
    J Diabetes Sci Technol; 2011 Sep; 5(5):1116-23. PubMed ID: 22027304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of vials and prefilled pens of a rapid-acting insulin analog on pharmacy budgets in a long-term care setting.
    Eby EL; Smolen LJ; Pitts AC; Krueger LA; Andrews JS
    Consult Pharm; 2014 Dec; 29(12):813-22. PubMed ID: 25521657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence, prevalence, and trend analysis of the use of insulin delivery systems in the United States (2005 to 2011).
    Perez-Nieves M; Jiang D; Eby E
    Curr Med Res Opin; 2015 May; 31(5):891-9. PubMed ID: 25710707
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.